AHZ will it keep moving forward, page-41

Allied’s ADAPT®-treated tissue demonstrates positive results of tissue repair in
abdominal hernia and pelvic floor reconstructions
 ADAPT®-treated tissue showed no evidence of infections, erosions or resorption in
the hernia repairs
 ADAPT®-treated tissue demonstrated reduced infections, erosions and provided
evidence of resorption in the pelvic floor
 The study was undertaken by the University of Leuven in Belgium
Brisbane, Australia, 10 January 2013
Allied Healthcare Group (ASX: AHZ) today announced positive results of a comparative study
which used ADAPT®-treated tissue as a bioprosthetic substitute for abdominal hernia repairs as
well as pelvic floor reconstructions in an experimental model. In the study the ADAPT® tissue
was superior or equal to the comparative synthetic implant.
No macroscopic evidence of calcification or visible immunological responses was found in the
explanted ADAPT®-treated tissue in both the hernia and pelvic floor reconstructions at the end
of the study period.
“These results are significant in building further revenue in areas outside of CardioCel® for
cardiovascular applications. With combined markets of over $750m we are excited about the
future prospects of building significant revenue for our Group and bringing to market innovative
regenerative tissue products developed from our Regenerative Medicine Division said Lee Rodne,
Allied Healthcare Group Managing Director.
Assessment of the physical properties of the explanted ADAPT®-treated tissues after six months
demonstrated a better outcome than the control in that the ADAPT®-treated tissue remained
stable and intact without any significant deformation of the original shape (configuration) and
size (dimensions) compared to synthetic meshes which tended to contract and shrink.
Recently Allied announced that its lead regenerative tissue product CardioCel®, made using the
ADAPT® process, showed significant tissue regeneration post implantation in cardiovascular
repair.
These results expand the potential for ADAPT®-treated tissue and open up opportunities to
develop additional ADAPT® engineered tissue products for application in different surgical areas.
The independent validation of these latest results confirms the regenerative performance of the
ADAPT® treated tissue and provides an opportunity to confirm the efficiency of the ADAPT®-
treated tissue in surgical repairs and reconstructions. These results provide additional evidence
that ADAPT® prepared tissue shows no signs of calcification and supports tissue regeneration,
clear advantages over existing tissue products available.